help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adams, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adams, J.
The Oncologist, Vol. 7, No. 1, 9-16, February 2002
© 2002 AlphaMed Press

Development of the Proteasome Inhibitor PS-341

Julian Adams

Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA

Correspondence: Julian Adams, Ph.D., Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, USA. Telephone: 617-551-3674; Fax: 617-679-7370; e-mail: jadams{at}mpi.com

Over the last decade, the critical role of the proteasome in cell-cycle regulation has become increasingly apparent. The proteasome, a multicatalytic protease present in all eukaryotic cells, is the primary component of the protein degradation pathway of the cell. By degrading regulatory proteins (or their inhibitors), the proteasome serves as a central conduit for many cellular regulatory signals and, thus, is a novel target for therapeutic drugs. PS-341 is a small molecule that is a potent and selective inhibitor of the proteasome. In vitro and mouse xenograft studies of PS-341 have shown antitumor activity in a variety of tumor types, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer, among others. Although PS-341 rapidly leaves the vascular compartment, a novel pharmacodynamic assay has shown that inhibition of proteasome—the biologic target—is dose dependent and reversible. These studies provided the rationale for a twice-weekly dosing schedule employed in ongoing clinical studies. Phase I trials in a variety of tumor types have shown PS-341 to be well tolerated, and phase II trials in several hematologic malignancies and solid tumor types are now in progress. Efficacy and safety data from the most advanced of these, a phase II multicenter trial in myeloma, will be available in early 2002.

Key Words. Antineoplastic agents • Boronic acids • Enzyme inhibitors (administration and dose) • NF-{kappa}B (antagonists and inhibitors) • Hematologic neoplasms (drug therapy) • Multienzyme complexes (antagonists and inhibitors) • 26S Proteasome • Multiple myeloma




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma
Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. Gao, J. Zhang, X. Si, J. Wong, C. Cheung, B. McManus, and H. Luo
Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H401 - H408.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Li, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao
Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-{kappa}B Transcriptional Activity
Clin. Cancer Res., April 1, 2007; 13(7): 2178 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth
Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood, October 1, 2006; 108(7): 2165 - 2172.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Teraishi, W. Guo, L. Zhang, F. Dong, J. J. Davis, T. Sasazuki, S. Shirasawa, J. Liu, and B. Fang
Activation of Sterile20-Like Kinase 1 in Proteasome Inhibitor Bortezomib-Induced Apoptosis in Oncogenic K-ras-Transformed Cells.
Cancer Res., June 15, 2006; 66(12): 6072 - 6079.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Kersting, J Packeisen, B Leidinger, B Brandt, R von Wasielewski, W Winkelmann, P J van Diest, G Gosheger, and H Buerger
Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas
J. Clin. Pathol., June 1, 2006; 59(6): 585 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Dublet, A. Ruello, M. Pederzoli, E. Hajjar, M. Courbebaisse, S. Canteloup, N. Reuter, and V. Witko-Sarsat
Cleavage of p21/WAF1/CIP1 by Proteinase 3 Modulates Differentiation of a Monocytic Cell Line: MOLECULAR ANALYSIS OF THE CLEAVAGE SITE
J. Biol. Chem., August 26, 2005; 280(34): 30242 - 30253.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Dai, M. Rahmani, X.-Y. Pei, P. Dent, and S. Grant
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms
Blood, July 15, 2004; 104(2): 509 - 518.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. E. Denlinger, M. D. Keller, M. W. Mayo, R. M. Broad, and D. R. Jones
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1078 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Helbig, K. W. Christopherson II, P. Bhat-Nakshatri, S. Kumar, H. Kishimoto, K. D. Miller, H. E. Broxmeyer, and H. Nakshatri
NF-{kappa} B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4
J. Biol. Chem., June 6, 2003; 278(24): 21631 - 21638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. V. Lee, R. Schiff, X. Cui, D. Sachdev, D. Yee, A. P. Gilmore, C. H. Streuli, S. Oesterreich, and D. L. Hadsell
New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation
Clin. Cancer Res., January 1, 2003; 9(1): 516s - 523s.
[Abstract] [Full Text]

Home page
 The OncologistHome page
J. Baselga
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Oncologist, August 15, 2002; 7(90004): 2 - 8.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Ranson
ZD1839 (IressaTM): For More Than Just Non-Small Cell Lung Cancer
Oncologist, August 15, 2002; 7(90004): 16 - 24.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.